Robust Optimal Design for the Estimation of Hyperparameters in Population Pharmacokinetics
The expectation of the determinant of the inverse of the population Fisher information matrix is proposed as a criterion to evaluate and optimize designs for the estimation of population pharmacokinetic (PK) parameters. Given a PK model, a measurement error model, a parametric distribution of the pa...
Saved in:
| Published in: | Journal of pharmacokinetics and biopharmaceutics Vol. 26; no. 6; pp. 689 - 716 |
|---|---|
| Main Authors: | , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
New York, NY
Plenum
01.12.1998
Springer Nature B.V |
| Subjects: | |
| ISSN: | 0090-466X, 1567-567X, 1573-8744 |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | The expectation of the determinant of the inverse of the population Fisher information matrix is proposed as a criterion to evaluate and optimize designs for the estimation of population pharmacokinetic (PK) parameters. Given a PK model, a measurement error model, a parametric distribution of the parameters and a prior distribution representing the belief about the hyperparameters to be estimated, the EID criterion is minimized in order to find the optimal population design. In this approach, a group is defined as a number of subjects to whom the same sampling schedule (i.e., the number of samples and their timing) is applied. The constraints, which are defined a priori, are the number of groups, the size of each group and the number of samples per subject in each group. The goal of the optimization is to determine the optimal sampling times in each group. This criterion is applied to a one-compartment open model with first-order absorption. The error model is either homoscedastic or heteroscedastic with constant coefficient of variation. Individual parameters are assumed to arise from a lognormal distribution with mean vector M and covariance matrix C. Uncertainties about the M and C are accounted for by a prior distribution which is normal for M and Wishart for C. Sampling times are optimized by using a stochastic gradient algorithm. Influence of the number of different sampling schemes, the number of subjects per sampling schedule, the number of samples per subject in each sampling scheme, the uncertainties on M and C and the assumption about the error model and the dose have been investigated. |
|---|---|
| AbstractList | The expectation of the determinant of the inverse of the population Fisher information matrix is proposed as a criterion to evaluate and optimize designs for the estimation of population pharmacokinetic (PK) parameters. Given a PK model, a measurement error model, a parametric distribution of the parameters and a prior distribution representing the belief about the hyperparameters to be estimated, the EID criterion is minimized in order to find the optimal population design. In this approach, a group is defined as a number of subjects to whom the same sampling schedule (i.e., the number of samples and their timing) is applied. The constraints, which are defined a priori, are the number of groups, the size of each group and the number of samples per subject in each group. The goal of the optimization is to determine the optimal sampling times in each group. This criterion is applied to a one-compartment open model with first-order absorption. The error model is either homoscedastic or heteroscedastic with constant coefficient of variation. Individual parameters are assumed to arise from a lognormal distribution with mean vector M and covariance matrix C. Uncertainties about the M and C are accounted for by a prior distribution which is normal for M and Wishart for C. Sampling times are optimized by using a stochastic gradient algorithm. Influence of the number of different sampling schemes, the number of subjects per sampling schedule, the number of samples per subject in each sampling scheme, the uncertainties on M and C and the assumption about the error model and the dose have been investigated. [PUBLICATION ABSTRACT] The expectation of the determinant of the inverse of the population Fisher information matrix is proposed as a criterion to evaluate and optimize designs for the estimation of population pharmacokinetic (PK) parameters. Given a PK model, a measurement error model, a parametric distribution of the parameters and a prior distribution representing the belief about the hyperparameters to be estimated, the EID criterion is minimized in order to find the optimal population design. In this approach, a group is defined as a number of subjects to whom the same sampling schedule (i.e., the number of samples and their timing) is applied. The constraints, which are defined a priori, are the number of groups, the size of each group and the number of samples per subject in each group. The goal of the optimization is to determine the optimal sampling times in each group. This criterion is applied to a one-compartment open model with first-order absorption. The error model is either homoscedastic or heteroscedastic with constant coefficient of variation. Individual parameters are assumed to arise from a lognormal distribution with mean vector M and covariance matrix C. Uncertainties about the M and C are accounted for by a prior distribution which is normal for M and Wishart for C. Sampling times are optimized by using a stochastic gradient algorithm. Influence of the number of different sampling schemes, the number of subjects per sampling schedule, the number of samples per subject in each sampling scheme, the uncertainties on M and C and the assumption about the error model and the dose have been investigated. The expectation of the determinant of the inverse of the population Fisher information matrix is proposed as a criterion to evaluate and optimize designs for the estimation of population pharmacokinetic (PK) parameters. Given a PK model, a measurement error model, a parametric distribution of the parameters and a prior distribution representing the belief about the hyperparameters to be estimated, the EID criterion is minimized in order to find the optimal population design. In this approach, a group is defined as a number of subjects to whom the same sampling schedule (i.e., the number of samples and their timing) is applied. The constraints, which are defined a priori, are the number of groups, the size of each group and the number of samples per subject in each group. The goal of the optimization is to determine the optimal sampling times in each group. This criterion is applied to a one-compartment open model with first-order absorption. The error model is either homoscedastic or heteroscedastic with constant coefficient of variation. Individual parameters are assumed to arise from a lognormal distribution with mean vector M and covariance matrix C. Uncertainties about the M and C are accounted for by a prior distribution which is normal for M and Wishart for C. Sampling times are optimized by using a stochastic gradient algorithm. Influence of the number of different sampling schemes, the number of subjects per sampling schedule, the number of samples per subject in each sampling scheme, the uncertainties on M and C and the assumption about the error model and the dose have been investigated.The expectation of the determinant of the inverse of the population Fisher information matrix is proposed as a criterion to evaluate and optimize designs for the estimation of population pharmacokinetic (PK) parameters. Given a PK model, a measurement error model, a parametric distribution of the parameters and a prior distribution representing the belief about the hyperparameters to be estimated, the EID criterion is minimized in order to find the optimal population design. In this approach, a group is defined as a number of subjects to whom the same sampling schedule (i.e., the number of samples and their timing) is applied. The constraints, which are defined a priori, are the number of groups, the size of each group and the number of samples per subject in each group. The goal of the optimization is to determine the optimal sampling times in each group. This criterion is applied to a one-compartment open model with first-order absorption. The error model is either homoscedastic or heteroscedastic with constant coefficient of variation. Individual parameters are assumed to arise from a lognormal distribution with mean vector M and covariance matrix C. Uncertainties about the M and C are accounted for by a prior distribution which is normal for M and Wishart for C. Sampling times are optimized by using a stochastic gradient algorithm. Influence of the number of different sampling schemes, the number of subjects per sampling schedule, the number of samples per subject in each sampling scheme, the uncertainties on M and C and the assumption about the error model and the dose have been investigated. |
| Author | Tod, Michel Mentré, France Merlé, Yann Mallet, Alain |
| Author_xml | – sequence: 1 givenname: Michel surname: Tod fullname: Tod, Michel – sequence: 2 givenname: France surname: Mentré fullname: Mentré, France – sequence: 3 givenname: Yann surname: Merlé fullname: Merlé, Yann – sequence: 4 givenname: Alain surname: Mallet fullname: Mallet, Alain |
| BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1797201$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/10485081$$D View this record in MEDLINE/PubMed |
| BookMark | eNptkc1rFTEUxYNU7Gt17U6CiLuxyeRz3D1qa4VCiyiIm3AnL7GpM5Npkln0vzev70mxuDpw-Z3D5ZwjdDDFySH0mpIPlLTsZP2xClGEEaIkZc_QigrFGq04P0ArQjrScCl_HKKjnG8JIVoI-QIdUsK1IJqu0M-vsV9ywVdzCSMM-JPL4deEfUy43Dh8lrfnEuKEo8cX97NLMyQYXXEp4zDh6zgvww64voE0go2_w-RKsPkleu5hyO7VXo_R9_Ozb6cXzeXV5y-n68vGcipK42i3kY63QqgOQFjtpQTvGbSt9sKC2-hWKqu4kMpx1_kNZQC96gnVPcieHaP3u9w5xbvF5WLGkK0bBphcXLKRXc1mTFfw7RPwNi5pqr-ZjsqWE0pEhd7soaUf3cbMqRaQ7s3fyirwbg9AtjD4BJMN-ZFTnWrJFhM7zKaYc3Le2FAeiioJwlDzzHZBszb_LFh9J098jx_83_EHb_ybzg |
| CODEN | JPBPBJ |
| CitedBy_id | crossref_primary_10_1208_aapsj070241 crossref_primary_10_1111_j_1742_7843_2009_00533_x crossref_primary_10_2165_00003088_200847040_00002 crossref_primary_10_1023_B_JOPA_0000013000_59346_9a crossref_primary_10_1007_s10928_006_9046_9 crossref_primary_10_2165_00003088_200948020_00002 crossref_primary_10_1023_A_1011534830530 crossref_primary_10_1007_s10928_005_2102_z crossref_primary_10_1007_s10928_008_9104_6 crossref_primary_10_1016_j_cmpb_2005_07_001 crossref_primary_10_1007_s10928_009_9123_y crossref_primary_10_1016_S0169_2607_01_00178_X crossref_primary_10_1038_sj_bmt_1703207 crossref_primary_10_1080_19466315_2018_1458647 crossref_primary_10_1016_j_cmpb_2005_02_005 crossref_primary_10_1177_0091270011423661 crossref_primary_10_1007_s11222_007_9023_1 crossref_primary_10_1002_sim_1041 crossref_primary_10_1007_s11129_008_9045_9 crossref_primary_10_1002_pds_1504 crossref_primary_10_1007_s10928_005_0078_3 crossref_primary_10_1097_FTD_0b013e318039b478 crossref_primary_10_1002_jps_24417 crossref_primary_10_1002_sim_1695 crossref_primary_10_1111_1467_9876_04847 crossref_primary_10_1023_A_1011035028755 crossref_primary_10_1046_j_1440_1681_2001_03546_x crossref_primary_10_1016_j_pharmthera_2012_10_005 crossref_primary_10_1080_15598608_2007_10411843 crossref_primary_10_1007_s10928_009_9135_7 crossref_primary_10_1002_sim_7436 crossref_primary_10_1007_s10928_009_9114_z crossref_primary_10_1177_096228029900800302 crossref_primary_10_1007_s10928_005_0014_6 crossref_primary_10_1081_BIP_120019267 crossref_primary_10_3109_00498250701553315 crossref_primary_10_1080_10543400701514007 crossref_primary_10_1007_s40262_016_0393_4 crossref_primary_10_1023_A_1011583210549 |
| Cites_doi | 10.1109/TAC.1974.1100716 10.1093/biomet/84.2.429 10.1016/0025-5564(85)90068-9 10.1080/01621459.1966.10502018 10.1023/A:1016267811074 10.1016/0169-2607(96)01721-X 10.1007/BF01070904 10.1214/aoms/1177706705 10.4153/CJM-1960-030-4 10.1007/BF01062273 10.1007/BF01062528 10.1016/0025-5564(90)90141-K 10.1023/A:1025701327672 10.1177/009286159502900321 10.1007/s002280050199 10.1007/BF03036255 10.1007/BF03190258 10.2165/00003088-199222060-00004 10.1016/0025-5564(88)90097-1 10.2165/00003088-199630020-00001 10.1146/annurev.pa.32.040192.001153 10.1007/BF02353491 10.1016/0010-4809(72)90051-1 10.1016/0005-1098(90)90116-Y |
| ContentType | Journal Article |
| Copyright | 1999 INIST-CNRS Plenum Publishing Corporation 1998 |
| Copyright_xml | – notice: 1999 INIST-CNRS – notice: Plenum Publishing Corporation 1998 |
| DBID | AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 3V. 7U9 7X7 7XB 88E 8AO 8FI 8FJ 8FK ABUWG AFKRA BENPR CCPQU FYUFA GHDGH H94 K9. M0S M1P M7N PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 |
| DOI | 10.1023/A:1020703007613 |
| DatabaseName | CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Virology and AIDS Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central ProQuest One Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Medical Database Algology Mycology and Protozoology Abstracts (Microbiology C) Proquest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest One Academic Middle East (New) ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Pharma Collection ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Algology Mycology and Protozoology Abstracts (Microbiology C) Health & Medical Research Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) Virology and AIDS Abstracts ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | ProQuest One Academic Middle East (New) MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1573-8744 |
| EndPage | 716 |
| ExternalDocumentID | 2561633391 10485081 1797201 10_1023_A_1020703007613 |
| Genre | Journal Article Feature |
| GroupedDBID | -~C .86 .GJ 06D 28- 29L 29~ 2LR 3O- 406 40D 40E 53G 5GY 5RE 8UJ 95- 95. 95~ 96X AABHQ AARTL AAYXX ABFTV ABJNI ABJOX ABKCH ABQSL ACGFS ADHKG ADURQ ADYFF AEGNC AEXYK AGDGC AGQPQ AI. AJRNO ALMA_UNASSIGNED_HOLDINGS AMKLP ASPBG AVWKF B-. BBWZM BGNMA CAG CITATION COF CS3 DPUIP F5P FNLPD G-Y G-Z IHE I~Z KDC KOV KOW LAK M4Y MA- N2Q NB0 NQJWS NU0 OVD PF0 R4E RHV RNI ROL RPX RSV RZC RZE SAP SBY SDH SNX SOJ TEORI U2A UG4 VH1 W48 WK6 ZGI ZXP ~EX IQODW CGR CUY CVF ECM EIF NPM --- -Y2 .VR 06C 0R~ 0VY 1N0 1SB 203 2J2 2JN 2JY 2KG 2KM 2P1 2VQ 2~H 30V 3V. 4.4 408 409 5VS 67N 67Z 6NX 78A 7U9 7X7 7XB 88E 8AO 8FI 8FJ 8FK AAAVM AAHNG AAIAL AAJBT AAJKR AANXM AANZL AAPKM AARHV AASML AATNV AAWCG AAYIU AAYQN AAYTO ABAKF ABBBX ABBRH ABBXA ABDBE ABDZT ABECU ABFSG ABHLI ABKTR ABMNI ABMQK ABNWP ABPLI ABQBU ABRTQ ABSXP ABTEG ABTHY ABTKH ABTMW ABULA ABUWG ABWNU ABXPI ACAOD ACBXY ACGFO ACHSB ACHXU ACIWK ACKNC ACMDZ ACMLO ACOKC ACOMO ACPIV ACPRK ACREN ACSTC ACZOJ ADBBV ADHHG ADHIR ADKPE ADRFC ADTPH ADYOE ADZKW AEBTG AEFQL AEGAL AEJHL AEJRE AEKMD AEMSY AENEX AEOHA AEPYU AESKC AETLH AEVLU AEZWR AFBBN AFDZB AFFHD AFGCZ AFHIU AFKRA AFLOW AFRAH AFWTZ AFYQB AFZKB AGAYW AGGDS AGJBK AGMZJ AGQEE AGQMX AGRTI AGWZB AGYKE AHBYD AHKAY AHMBA AHPBZ AHSBF AHWEU AHYZX AIAKS AIGIU AILAN AITGF AIXLP AJBLW AJZVZ AKMHD ALWAN AMTXH AMXSW AMYQR AOCGG ARMRJ ATHPR AXYYD AYFIA AZFZN BA0 BDATZ BENPR BPHCQ BSONS BVXVI CCPQU CSCUP DDRTE DL5 DNIVK EBLON EBS EIOEI EJD EN4 EPAXT ESBYG FEDTE FERAY FFXSO FIGPU FINBP FRRFC FSGXE FWDCC FYUFA GGCAI GGRSB GJIRD GNWQR GQ7 GQ8 GXS H94 HF~ HG5 HG6 HMCUK HMJXF HQYDN HRMNR HVGLF HZ~ I09 IJ- IKXTQ ITM IWAJR IXC IZIGR IZQ I~X J-C J0Z JBSCW JCJTX JZLTJ K9. KPH LLZTM LSO M1P M7N N9A NPVJJ O9- O93 O9G O9I O9J OAM P19 P2P PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS PROAC PSQYO PT4 PT5 Q2X QOK QOR QOS R89 R9I RRX RZK S16 S27 S3A S3B SBL SDM SHX SJYHP SNE SNPRN SOHCF SPISZ SRMVM SSLCW SZN T13 TSG TSK TSV TUC TUS U9L UKHRP UOJIU UTJUX UZXMN VC2 VFIZW W23 WJK WK8 YLTOR Z45 ZMTXR ZOVNA 7X8 |
| ID | FETCH-LOGICAL-c415t-e19d6e425579aa5c8f66aff3a228f5caed8267c74567e4e9fd13aab7b018ba6b3 |
| IEDL.DBID | 7X7 |
| ISICitedReferencesCount | 45 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000080410400004&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0090-466X 1567-567X |
| IngestDate | Fri Jul 11 02:54:13 EDT 2025 Tue Nov 04 23:37:53 EST 2025 Wed Feb 19 01:31:58 EST 2025 Mon Jul 21 09:13:30 EDT 2025 Sat Nov 29 07:49:23 EST 2025 Tue Nov 18 19:41:54 EST 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 6 |
| Keywords | Human Optimal sampling Compartmental model Methodology Simulation Experimental design Estimation Population Kinetic parameter Pharmacokinetics Optimization Sampling frequency |
| Language | English |
| License | CC BY 4.0 |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c415t-e19d6e425579aa5c8f66aff3a228f5caed8267c74567e4e9fd13aab7b018ba6b3 |
| Notes | SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 14 ObjectType-Article-1 ObjectType-Feature-2 content type line 23 |
| PMID | 10485081 |
| PQID | 916240105 |
| PQPubID | 55470 |
| PageCount | 28 |
| ParticipantIDs | proquest_miscellaneous_69255338 proquest_journals_916240105 pubmed_primary_10485081 pascalfrancis_primary_1797201 crossref_citationtrail_10_1023_A_1020703007613 crossref_primary_10_1023_A_1020703007613 |
| PublicationCentury | 1900 |
| PublicationDate | 1998-12-01 |
| PublicationDateYYYYMMDD | 1998-12-01 |
| PublicationDate_xml | – month: 12 year: 1998 text: 1998-12-01 day: 01 |
| PublicationDecade | 1990 |
| PublicationPlace | New York, NY |
| PublicationPlace_xml | – name: New York, NY – name: United States – name: New York |
| PublicationTitle | Journal of pharmacokinetics and biopharmaceutics |
| PublicationTitleAlternate | J Pharmacokinet Biopharm |
| PublicationYear | 1998 |
| Publisher | Plenum Springer Nature B.V |
| Publisher_xml | – name: Plenum – name: Springer Nature B.V |
| References | E. I. Ette (409593_CR9) 1995; 12 E. Walter (409593_CR16) 1987; 253 J. Kiefer (409593_CR27) 1960; 12 L. B. Sheiner (409593_CR2) 1992; 32 M. Tod (409593_CR21) 1996; 50 A. H. Thomson (409593_CR5) 1992; 22 V. Breant (409593_CR11) 1996; 51 E. N. Jonsson (409593_CR10) 1996; 24 P. Burtin (409593_CR4) 1996; 22 S. Vozeh (409593_CR3) 1996; 30 N. L. Johnson (409593_CR19) 1972 E. Walter (409593_CR14) 1990; 26 H. Kesten (409593_CR22) 1958; 29 409593_CR28 M. Tod (409593_CR25) 1997; 25 L. Pronzato (409593_CR17) 1985; 75 G. N. Saridis (409593_CR20) 1974; 19 409593_CR23 L. Pronzato (409593_CR26) 1988; 89 D. Z. D'Argenio (409593_CR15) 1981; 9 P. L. Odell (409593_CR24) 1966; 313 J. Wang (409593_CR8) 1992; 20 D. Z. D'Argenio (409593_CR18) 1990; 99 F. Mentré (409593_CR13) 1997; 84 Y. Hashimoto (409593_CR7) 1991; 19 L. B. Sheiner (409593_CR1) 1972; 5 F. Mentré (409593_CR12) 1995; 29 M. K. Al-Banna (409593_CR6) 1990; 18 |
| References_xml | – volume: 19 start-page: 798 year: 1974 ident: 409593_CR20 publication-title: IEEE Trans. Automat. Contr. doi: 10.1109/TAC.1974.1100716 – volume: 84 start-page: 429 year: 1997 ident: 409593_CR13 publication-title: Biometrika doi: 10.1093/biomet/84.2.429 – volume: 75 start-page: 103 year: 1985 ident: 409593_CR17 publication-title: Math. Biosci. doi: 10.1016/0025-5564(85)90068-9 – volume: 313 start-page: 199 year: 1966 ident: 409593_CR24 publication-title: J. Am. Statist. Soc. doi: 10.1080/01621459.1966.10502018 – volume: 12 start-page: 729 year: 1995 ident: 409593_CR9 publication-title: Pharm. Res. doi: 10.1023/A:1016267811074 – volume: 50 start-page: 13 year: 1996 ident: 409593_CR21 publication-title: Comput. Meth. Prog. Biomed. doi: 10.1016/0169-2607(96)01721-X – volume: 9 start-page: 739 year: 1981 ident: 409593_CR15 publication-title: J. Pharmacokin. Biopharm. doi: 10.1007/BF01070904 – volume: 29 start-page: 41 year: 1958 ident: 409593_CR22 publication-title: Ann. Math. Statist. doi: 10.1214/aoms/1177706705 – volume: 12 start-page: 362 year: 1960 ident: 409593_CR27 publication-title: Can. J. Math. doi: 10.4153/CJM-1960-030-4 – volume: 253 start-page: R530 year: 1987 ident: 409593_CR16 publication-title: Am. J. Physiol. – ident: 409593_CR23 – volume: 18 start-page: 347 year: 1990 ident: 409593_CR6 publication-title: J. Pharmacokin. Biopharm. doi: 10.1007/BF01062273 – volume: 20 start-page: 279 year: 1992 ident: 409593_CR8 publication-title: J. Pharmacokin. Biopharm. doi: 10.1007/BF01062528 – volume: 99 start-page: 105 year: 1990 ident: 409593_CR18 publication-title: Math. Biosci. doi: 10.1016/0025-5564(90)90141-K – volume: 25 start-page: 515 year: 1997 ident: 409593_CR25 publication-title: J. Pharmacokin. Biopharm. doi: 10.1023/A:1025701327672 – volume: 29 start-page: 997 year: 1995 ident: 409593_CR12 publication-title: Drug Inform. J. doi: 10.1177/009286159502900321 – volume: 51 start-page: 283 year: 1996 ident: 409593_CR11 publication-title: Eur. J. Clin. Pharmacol. doi: 10.1007/s002280050199 – volume: 19 start-page: 333 year: 1991 ident: 409593_CR7 publication-title: J. Pharmacokin. Biopharm. doi: 10.1007/BF03036255 – start-page: 158 volume-title: Distributions in Statistics: Continuous Multivariate Distributions year: 1972 ident: 409593_CR19 – ident: 409593_CR28 – volume: 22 start-page: 105 year: 1996 ident: 409593_CR4 publication-title: Eur. J. Drug Metab. Pharmacokin doi: 10.1007/BF03190258 – volume: 22 start-page: 447 year: 1992 ident: 409593_CR5 publication-title: Clin. Pharmacokin. doi: 10.2165/00003088-199222060-00004 – volume: 89 start-page: 161 year: 1988 ident: 409593_CR26 publication-title: Math. Biosci. doi: 10.1016/0025-5564(88)90097-1 – volume: 30 start-page: 81 year: 1996 ident: 409593_CR3 publication-title: Clin. Pharmacokin. doi: 10.2165/00003088-199630020-00001 – volume: 32 start-page: 185 year: 1992 ident: 409593_CR2 publication-title: Ann. Rev. Pharmacol. Toxicol. doi: 10.1146/annurev.pa.32.040192.001153 – volume: 24 start-page: 245 year: 1996 ident: 409593_CR10 publication-title: J. Pharmacokin. Biopharm. doi: 10.1007/BF02353491 – volume: 5 start-page: 441 year: 1972 ident: 409593_CR1 publication-title: Comput. Biomed. Res. doi: 10.1016/0010-4809(72)90051-1 – volume: 26 start-page: 195 year: 1990 ident: 409593_CR14 publication-title: Automatica doi: 10.1016/0005-1098(90)90116-Y |
| SSID | ssj0008556 ssj0016520 |
| Score | 1.6747055 |
| Snippet | The expectation of the determinant of the inverse of the population Fisher information matrix is proposed as a criterion to evaluate and optimize designs for... |
| SourceID | proquest pubmed pascalfrancis crossref |
| SourceType | Aggregation Database Index Database Enrichment Source |
| StartPage | 689 |
| SubjectTerms | Biological and medical sciences General pharmacology Humans Medical sciences Models, Biological Pharmacokinetics Pharmacokinetics. Pharmacogenetics. Drug-receptor interactions Pharmacology. Drug treatments Population Surveillance Studies |
| Title | Robust Optimal Design for the Estimation of Hyperparameters in Population Pharmacokinetics |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/10485081 https://www.proquest.com/docview/916240105 https://www.proquest.com/docview/69255338 |
| Volume | 26 |
| WOSCitedRecordID | wos000080410400004&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1573-8744 dateEnd: 20171231 omitProxy: false ssIdentifier: ssj0016520 issn: 0090-466X databaseCode: 7X7 dateStart: 19970201 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1573-8744 dateEnd: 20171231 omitProxy: false ssIdentifier: ssj0016520 issn: 0090-466X databaseCode: BENPR dateStart: 19970201 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVAVX databaseName: Springer LINK customDbUrl: eissn: 1573-8744 dateEnd: 20001231 omitProxy: false ssIdentifier: ssj0008556 issn: 0090-466X databaseCode: RSV dateStart: 19730101 isFulltext: true titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22 providerName: Springer Nature |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LT9wwEB7x6AEJFcqrKYX6UKEeCDQv2zlVFBZxqLbRlqIVl8hxbAm1JNv1biX-PWMnm2UrwaWHREriOJZnPPNNZjwD8JEGigtVaD8p0TaJmUA5qMrSTxRLlGSFLp0H_-Yb6_f5cJhmbWyOacMqZzLRCeqylvYf-SnCGFQ-iAa-jP74tmiUda62FTSWYdVWzbZszoadvRXQxGVlRAuF-XgM_8nsEzput3Z8tKCU1kfC4PzoprDF88jTaaDLjf8c-ya8bqEnOWt45Q0sqWoLjrImd_XDMbmeb8Uyx-SIZPOs1g_bcDuoi6mZkO8oY-6xmwsX-kEQ8xLEkKRn7G1LZVJrcoXW7dhmFb-30TaG3FUk6yqFdR3_QoRrP7YDPy971-dXfluYwZeo7ye-CtKSKlztCUuFSCTXlAqtIxGGXCdSqBKNFiYZgjOmYpXqMoiEKFjxOeCFoEW0CytVXam3QCRaKIppToXLxEeLmCUyjhHHhTHXKvLgZEaZXLZZy23xjN-5856HUX6WL5DSg0_dC6MmYcfzTQ8WSD1vz1KGwMiD_Rk583Zlm7yjpQcfuqe4JK2fRVSqnpqcpjgzaPp7sNfwy5OBxBwRcfDuxZ73Yc3tfHRBM-9hZTKeqgN4Jf9O7sz40PG4O_NDWP3a62cDvBr8uHkEmn8HZw |
| linkProvider | ProQuest |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwEB6VLRJIiPcjlFIfoOLQAEkcOzkgVOhWW3VZomqLVlyC49hSBU2WzS5ofxT_kbHzWBap3HrgkEviTBLn8_gbz3gG4BnzVCRUpt0wR9uEcoF6UOW5GyoeKskznVsP_qchH42iySRONuBXuxfGhFW2OtEq6ryUZo38FdIYnHyQDbydfndN0SjjXG0raNSoOFbLn2ixVW-ODvD3Pvf9w_74_cBtigq4Euequau8OGcKkRryWIhQRpoxoXUgfD_SoRQqR8LNJUdiwRVVsc69QIiMZ6-9KBMsC1DuFdikAWVhDzbf9UfJSee2YKHNA4k2EXfxmPyVS8i348usHARr0-CNqajwj-i6lMbFXNfOeYe3_rPeug03G3JN9uvRcAc2VHEXdpM6O_dyj4xXm82qPbJLklXe7uU9-HxSZotqTj6iFj1HMQc2uIUgqyfIkkm_MqcNjkmpyQDt95nJm35u4okqclaQpKuF1gn-ihzePOw-nF7Kdz-AXlEW6hEQiTaY4jpiwuYaZBnloaQUmapPI60CB162SEhlk5fdlAf5ltr4AD9I99M16DjworthWqckubjp9hq0Vu15zJH6ObDVwidtdFeVdthxYKe7ikrHeJJEocpFlbIYeyYIIgce1vj840VohJzfe_xPyTtwbTD-MEyHR6PjLbhu93naEKEn0JvPFmobrsof87Nq9rQZYQS-XDZMfwPT32Qx |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwEB6VLUKVEO9CKKU-QMWhoeRp54BQYXfVqtUSVaVacQmOY0sVNFnWu6D9afw7xs5jWaRy64FDLokzSZzP42884xmAF7EnGZe5cqMCbZOQctSDsijcSNJICpqrwnrwz0_oaMTG4yRdg1_tXhgTVtnqRKuoi0qYNfJ9pDE4-SAb2FdNVETaH76bfHdNASnjaG2radQIOZaLn2i96bdHffzVL31_ODj7cOg2BQZcgfPWzJVeUsQSURvRhPNIMBXHXKmA-z5TkeCyQPJNBUWSQWUoE1V4Aec5zd94LOdxHqDcG7BOA7R5erD-fjBKTzsXRhzZnJBoH1EXj_FfeYV8O9bMKkKwMiXennCNf0fVZTWu5r12_hve_Y977h7caUg3OahHyX1Yk-UD2E3rrN2LPXK23ISm98guSZf5vBcP4fNplc_1jHxE7XqJYvo26IUg2yfInslAm9MG36RS5BDt-qnJp35p4ow0uShJ2tVI6wR_RW5vHvYIPl3Ld29Cr6xK-QSIQNtMUsVibnMQxnlIIxGGyGD9kCkZOPC6RUUmmnztpmzIt8zGDfhBdpCtwMiBV90NkzpVydVNt1dgtmxPE4qU0IGtFkpZo9N01uHIgZ3uKioj42HipazmOosT7JkgYA48rrH6x4uEDG0B7-k_Je_ALcRmdnI0Ot6CDbv900YOPYPebDqX23BT_Jhd6OnzZrAR-HLdKP0NnUNs9A |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Robust+Optimal+Design+for+the+Estimation+of+Hyperparameters+in+Population+Pharmacokinetics&rft.jtitle=Journal+of+pharmacokinetics+and+pharmacodynamics&rft.au=Tod%2C+Michel&rft.au=Mentr%C3%A9%2C+France&rft.au=Merl%C3%A9%2C+Yann&rft.au=Mallet%2C+Alain&rft.date=1998-12-01&rft.pub=Springer+Nature+B.V&rft.issn=1567-567X&rft.eissn=1573-8744&rft.volume=26&rft.issue=6&rft.spage=689&rft_id=info:doi/10.1023%2FA%3A1020703007613&rft.externalDBID=HAS_PDF_LINK&rft.externalDocID=2561633391 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0090-466X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0090-466X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0090-466X&client=summon |